Efficacy and safety of HER2 directed therapies for advanced HER2-mutant non-small-cell lung cancer - a systematic review and meta-analysis.
INTRODUCTION Recently, both HER2 tyrosine kinase inhibitors (TKIs) and antibody drug conjugates (ADCs) targeting HER2 have demonstrated clinically meaningful activity and received regulatory approval for advanced HER2-mutant NSCLC, although evidence is primarily derived from single-arm trials with modest sample sizes a...